(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Opioid Abuse
Medical University of South CarolinaSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Opioid Abuse cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NEPENTHE Member Companies of the Opioid PMR Consortium | Phase 4 | BB |
Oxycodone Member Companies of the Opioid PMR Consortium | Phase 4 | BB |
Tizanidine Stanford University | Phase 3 | B |
OXYMORPHONE CII Member Companies of the Opioid PMR Consortium | Phase 4 | B |
Duloxetine Scripps Health | Phase 2 | CCC |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE University of Alabama at Birmingham | Early Phase 1 | CCC |
Naltrexone Pfizer | Phase 1 | CC |
Same molecule, other indications
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →